Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
Date:10/7/2010

MILAN, Oct. 7 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

"It's been almost five years since the approval of Nexavar in its first indication, advanced kidney cancer, and since that time the continuum of development in other areas has produced clinically significant findings, leading to a second approval in unresectable liver cancer," said Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. "Our dedication to the development of Nexavar is demonstrated by the array of data being presented at this year's ESMO Congress as well as the ongoing clinical trial program evaluating Nexavar in a variety of treatment settings and patient types."

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 95 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators.

Important Safety Considerations For Patien
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- Research and Markets has announced the ... 2014 " report to their offering. ... a professional and in-depth study on the current state ... report provides a basic overview of the industry including ... meter market analysis is provided for both the international ...
(Date:8/26/2014)... design and architecture firm NBBJ announced today the expansion of its healthcare ... Rudy Widjaja will lead planning and design teams from NBBJ,s ... with healthcare clients in China , Taiwan ... well as the firm,s global network of healthcare experts.   ... at a time when the scope of the firm,s healthcare practice in ...
(Date:8/26/2014)... -- Research and Markets  has announced the addition ... report to their offering. Cytomegalovirus retinitis ... causative organism of this disease is cytomegalovirus, a herpes ... This disease can lead to permanent blindness if left ... the other eye if neglected. The virus is very ...
Breaking Medicine Technology:Global Glucose Meter Industry Report 2014 2Global Glucose Meter Industry Report 2014 3Leading Architectural Design Firm NBBJ Launches Healthcare Practice in China 2Leading Architectural Design Firm NBBJ Launches Healthcare Practice in China 3Leading Architectural Design Firm NBBJ Launches Healthcare Practice in China 4Leading Architectural Design Firm NBBJ Launches Healthcare Practice in China 5Global Cytomegalovirus Retinitis Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, Hospira and Shire 2Global Cytomegalovirus Retinitis Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, Hospira and Shire 3
... Mo., Oct. 4 A new study by researchers ... Kansas City, Mo., found that rapid electronic review of ... allowed for earlier diagnosis and treatment of potentially serious ... American Academy of Pediatrics National Conference and Exhibition in ...
... BURLINGTON, Mass., Oct. 4 Decision Resources, one of the ... issues finds that the non-small-cell lung cancer (NSCLC) drug market ... than $6.5 billion in 2019 in the United States, France, ... Pharmacor 2010 findings from the topic entitled Non-Small-Cell Lung ...
Cached Medicine Technology:New Study Shows Telemedicine Works to Effectively Identify Heart Problems in Children Far from a Specialized Medical Center 2The Non-Small-Cell Lung Cancer Drug Market Will Increase From Approximately $4 Billion in 2009 to More Than $6.5 Billion in 2019 2The Non-Small-Cell Lung Cancer Drug Market Will Increase From Approximately $4 Billion in 2009 to More Than $6.5 Billion in 2019 3
(Date:8/27/2014)... German . ... metastatic tumors. In case of pancreatic cancer, one of the ... 95% of the patients die within five years after the ... might reduce this mortality rate. For preclinical and clinical tests ... EUR 5 million from investors. This will allow for the ...
(Date:8/27/2014)... Phoenix, AZ (PRWEB) August 27, 2014 ... of experienced and knowledgeable Internet marketers reports record demand ... With a growing number of businesses across the country ... to leverage the Internet they are increasingly turning to ... of experience under its belt, Helix House features a ...
(Date:8/27/2014)... 2014 StartX , a nonprofit ... QB3 , a pioneering institute driving biotechnology innovation at ... life science laboratory customized for the needs of early ... 2,000 square-foot lab space, named “StartX-QB3 Labs,” is the ... Stanford Health Care focused on developing entrepreneurs from academia ...
(Date:8/27/2014)... August 27, 2014 Top10inaction, a professional ... IOS to Blackberry OS by name brands such as ... modern life necessity. Smartphone means a lot more than ... pictures, record videos and surf the internet with their ... of smartphones quickly. How to choose a right smartphone ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 A recent ... month found that the dental community disagrees on ... for their patients. Analysis of dental advice suggested that ... with no one technique more popular than the rest. ... is to brush and floss your teeth regularly,” said ...
Breaking Medicine News(10 mins):Health News:Preclinical development of tumor therapeutic agent starts 2Health News:Helix House Reports Record Demand For Marketing Services That Take Advantage Of Social Media 2Health News:Helix House Reports Record Demand For Marketing Services That Take Advantage Of Social Media 3Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 2Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 3Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 4Health News:Best Smartphones 2014 Revealed by Top10InAction.com 2Health News:Americans Confused About How to Brush Teeth 2
... expanded technology tools to support ... in marketplace -, LISLE, IL, June 5 /PRNewswire-FirstCall/ ... SXCI , TSX: SXC), a leading provider of,pharmacy ... Information Technology (HCIT) group to provide ongoing business,and technology ...
... longstanding symptoms, PORTLAND, Ore., June 5 As ... also exposes them to tick bites that can,result in ... in,the United States. A microscopic bacterial organism, Borrelia burgdorferi,carried ... the,incidence of Lyme disease remains low -- about 100,000 ...
... TUCSON, Ariz., June 5 You can lose 15 ... you are below your ideal weight,according to a new ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA03 ), Dow says ... diet. It,s,described in The Pen and Paper Diet and ...
... and facing ... major illnesses, RALEIGH, N.C., June 5 If living ... apple a day and picking,up a book from the Lulu.com Global Marketplace., ... share their expertise on how to stay healthy, wealthy,and wise, but so are ...
... Baby boomers and senior boomers,are getting bombarded with sales ... let the whirlwind messages and slick,marketing put you on ... N.,Darras, the nation,s leading disability and long term care ... all, it is important to take your time and ...
... LONDON and PHILADELPHIA, June 5 Thomson Reuters, ... and,professionals, today announced the addition of Prous Science ... Premium and Newport Vision,Premium solutions. An ROS focused ... according to an intermediate or reagent,used, number of ...
Cached Medicine News:Health News:SXC Health Solutions to provide technology services and support to major PBM 2Health News:When Are Antibiotics for Lyme Disease Medically Necessary? 2Health News:When Are Antibiotics for Lyme Disease Medically Necessary? 3Health News:Weight Management Solution Helps You Lose or Gain as Much Weight as You Choose 2Health News:Lulu.com Authors Strive to Help Readers Stay Healthy, Wealthy & Wise 2Health News:Lulu.com Authors Strive to Help Readers Stay Healthy, Wealthy & Wise 3Health News:Long Term Care - A Health Qualifying Product 2Health News:Thomson Reuters Adds Routes of Synthesis Data to Its Newport Horizon Premium and Newport Vision Premium Solutions 2
... The laser beam is delivered through an ultra ... gives the operator full freedom of movement when ... coupled with a wide range of handpieces. ... 11 mm and 16 mm. Straight and ...
Single use trocar with non-conductive sleeves for gaining and maintaining thoracic access., ,THORACOPORT™ devices are trocars used to gain access to the thoracic cavity for use in video assis...
VERSASTEP™ Reposable Short Single-Use For use with VERSASTEP™ Short Reusable Cannula, Dilator....
VersaStep™ Reposable Sterilization Trays....
Medicine Products: